Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Achalasia

In brief

The objectives of this study are as follows: In participants with primary Type I or II achalasia, following a single 5-mg dose of olinciguat (IW-1701), * To assess the safety and tolerability * To determine the effects on measures of esophageal function by high-resolution impedance manometry (HRIM) * To determine the pharmacokinetic (PK) parameters

Key facts

Study ID

NCT02931565

Run by

Cyclerion Therapeutics

People needed

9

Starts

2017-04-06

Expected to finish

2018-05-01

Last updated by the study team

2021-05-04

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Connecticut Clinical Research Foundation, Gastroenterology Institute — Bristol, Connecticut, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Washington University in St. Louis - School of Medicine — St Louis, Missouri, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• University of Utah School of Medicine, Division of Gastroenterology, Hepatology & Nutrition — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.